US12599625B2 - Nitrous Oxide Oxygen Inhalation Therapy for ARDS
Summary
The USPTO granted Patent US12599625B2 to Penland Foundation on April 14, 2026, covering nitrous oxide and oxygen inhalation therapy for treating ARDS and conditions caused by elevated cytokine levels. The patent, invented by Roland M. Williams, contains 22 claims classified under A61K 33/00 and A61P 11/16. The treatment method involves administering nitrous oxide and oxygen by inhalation before, during, and/or after ARDS occurs to address acute cytokine system activation from infections, injuries, or other conditions.
What changed
USPTO issued Patent US12599625B2 granting exclusive intellectual property rights to Penland Foundation for nitrous oxide and oxygen inhalation therapy methods treating ARDS caused by viral/bacterial infections, injuries, or cytokine storms. The patent includes 22 claims covering treatment administration before, during, and/or after ARDS occurrence, as well as post-ARDS chronic cytokine damage.
Competitors developing similar inhalation therapies for ARDS or cytokine-related conditions should conduct freedom-to-operate analyses to avoid infringing this granted patent. Healthcare providers and researchers exploring nitrous oxide-oxygen treatments should verify whether the technology is covered by this intellectual property protection when developing new clinical applications.
What to do next
- Monitor for updates
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Treatment of ARDS and other conditions caused by acutely elevated cytokine levels and post ARDS chronic cytokine production using inhaled anesthetics
Grant US12599625B2 Kind: B2 Apr 14, 2026
Assignee
Penland Foundation
Inventors
Roland M. Williams
Abstract
Nitrous oxide and oxygen for use in treating ARDS caused by viral and bacterial infections, injuries, or other conditions that have resulted in acute, excess activation of the cytokine system in a patient in need thereof is provided. The treatment comprises administering nitrous oxide and oxygen to the patient by inhalation before, during, and/or after ARDS occurs. It is also applicable for treating, alleviating, and/or preventing an aftereffect of said conditions. A composition, duration, an interval, and a total amount of nitrous oxide and oxygen depend on each patient's individual situation and needs. Inhalation of nitrous oxide and oxygen can also stop the post ARDS symptoms that remain after an acute ARDS condition such as, but not limited to viral infections, bacterial infections, injuries, or any condition that results from any cytokine storm. Inhalation of nitrous oxide and oxygen can also treat local cytokine damages caused by said conditions.
CPC Classifications
A61K 33/00 A61P 11/16 G01N 33/6863 G01N 2800/125 G01N 2800/52
Filing Date
2022-05-04
Application No.
17662068
Claims
22
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.